

NULISaseq™ lot and batch definitions and considerations for experimental design


INFO SHEET

Introduction

The scalable, high sensitivity NULISaseq assay provides the ability to multiplex the analysis of hundreds to potentially thousands of protein biomarkers. The manufacturing of the multiplex assays is highly controlled and goes through extensive QC. As with any antibody-based technology, lot to lot variation should be considered in the context of experimental design. This tech note describes Alamar’s lot and batch definitions.

Lot and batch definition

Each NULISaseq panel target kit is designated with a unique 7-digit lot number and 2-digit batch number. The individual antibodies are first combined into a liquid pool designated with an unique lot number as shown in figure 1. The lots are then allocated into batches for lyophilization and kitting (lot #XXXXXXXb1, b2, b3).



Experimental design considerations

Alamar has done extensive validation and shown excellent correlation between lots and batches. See Table 1. However, for studies where crossing between two lots is required, bridging samples should be used. Bridging samples are not required between batches for the same lot as the antibody pool remains consistent for those batches.

Further information on this topic can be found in the [NULISaseq Normalization Control and Quality Control](#) tech note.

Table 1. Example of lot and batch correlation from NULISaseq CNS Disease Panel 120.

	Mean R ²	Median R ²
Lot-to-lot	0.95	0.95
Batch-to-batch	0.98	0.98

Visit [AlamarBio.com](#) to learn more.

Alamar Biosciences, Inc.
47071 Bayside Parkway
Fremont, CA 94538
T +1 (510) 626-9888
E info@alamarbio.com

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
©2024 Alamar Biosciences, Inc. All rights reserved. Alamar, NULISA, NULISaseq and ARGO are trademarks of Alamar Biosciences, Inc. All other trademarks and/or service marks not owned by Alamar that appear are the property of their respective owners.
M1025-0425.1

